OR WAIT null SECS
© 2022 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2022 MJH Life Sciences™ and Formulary Watch. All rights reserved.
June 24, 2022
Byetta is used to control blood sugar in patients with diabetes. A new warning includes the risk of gallstones and gallbladder inflammation.
May 20, 2022
If insulin copays were capped at $35, Part D enrollees would save 29% on average, according to new analysis from Kaiser Family Foundation.
May 16, 2022
Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control.
March 29, 2022
Ozempic is now available in three doses to improve blood sugar in people with type 2 diabetes.
March 16, 2022
Allan Coukell, Civica’s senior vice president of public policy, discusses how the generic manufacturer is disrupting the market for insulins.
March 07, 2022
Once approved, the insulins will be available to patients for no more than $30 per vial.
November 24, 2021
Patients who are part of the Walgreen’s Prescription Savings Club can receive Semglee at up to 80% off the cash price.
November 23, 2021
OptumRx will favor the reference product Lantus on the Premium Formulary. The organization also released coverage information about other newly approved therapies.
November 16, 2021
Branded and unbranded versions of the interchangeable biosimilar to treat patients with diabetes are now available.
November 03, 2021
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.